{"id":"pth-followed-by-dose-dense-ac-of-fec","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"5-10","effect":"Cardiotoxicity"},{"rate":"80-90","effect":"Alopecia"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PTH targets HER2-positive cancer cells through trastuzumab (anti-HER2 monoclonal antibody) combined with paclitaxel (microtubule stabilizer). This is followed by dose-dense anthracycline-based chemotherapy (AC or FEC regimens) which intercalates DNA and generates reactive oxygen species to kill rapidly dividing cells. The sequential combination leverages different mechanisms of action to maximize efficacy in HER2-positive breast cancer.","oneSentence":"This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:19.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive early-stage breast cancer (neoadjuvant or adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PTH followed by dose dense AC of FEC","genericName":"PTH followed by dose dense AC of FEC","companyName":"Agendia","companyId":"agendia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer. Used for HER2-positive early-stage breast cancer (neoadjuvant or adjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}